全文获取类型
收费全文 | 26956篇 |
免费 | 2973篇 |
国内免费 | 844篇 |
专业分类
耳鼻咽喉 | 242篇 |
儿科学 | 394篇 |
妇产科学 | 330篇 |
基础医学 | 1237篇 |
口腔科学 | 634篇 |
临床医学 | 3983篇 |
内科学 | 2607篇 |
皮肤病学 | 197篇 |
神经病学 | 905篇 |
特种医学 | 632篇 |
外国民族医学 | 13篇 |
外科学 | 1893篇 |
综合类 | 3585篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 5819篇 |
眼科学 | 145篇 |
药学 | 3421篇 |
79篇 | |
中国医学 | 2148篇 |
肿瘤学 | 2506篇 |
出版年
2024年 | 190篇 |
2023年 | 698篇 |
2022年 | 1220篇 |
2021年 | 1416篇 |
2020年 | 1440篇 |
2019年 | 1112篇 |
2018年 | 1027篇 |
2017年 | 1126篇 |
2016年 | 1175篇 |
2015年 | 1207篇 |
2014年 | 2039篇 |
2013年 | 2210篇 |
2012年 | 1780篇 |
2011年 | 1835篇 |
2010年 | 1398篇 |
2009年 | 1318篇 |
2008年 | 1240篇 |
2007年 | 1165篇 |
2006年 | 1060篇 |
2005年 | 826篇 |
2004年 | 728篇 |
2003年 | 650篇 |
2002年 | 501篇 |
2001年 | 446篇 |
2000年 | 388篇 |
1999年 | 363篇 |
1998年 | 322篇 |
1997年 | 254篇 |
1996年 | 209篇 |
1995年 | 182篇 |
1994年 | 177篇 |
1993年 | 142篇 |
1992年 | 144篇 |
1991年 | 117篇 |
1990年 | 99篇 |
1989年 | 78篇 |
1988年 | 69篇 |
1987年 | 55篇 |
1986年 | 58篇 |
1985年 | 70篇 |
1984年 | 54篇 |
1983年 | 29篇 |
1982年 | 26篇 |
1981年 | 31篇 |
1980年 | 31篇 |
1979年 | 14篇 |
1978年 | 19篇 |
1977年 | 15篇 |
1976年 | 5篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
目的了解北京市房山区梅毒规划(2010—2020年)实施期间梅毒防治效果和各考核指标达标情况,为下一步制定有效的梅毒防治策略提供科学依据。方法根据《中国预防与控制梅毒规划(2010—2020年)》(以下简称《梅控规划》)终期评估的要求,通过专网、现场调查、APP答题等方式对涉及的16个指标进行收集,并将16个指标划分为梅毒防治保障措施的落实、防治工作开展和防治效果3个层面进行评估,同时将评估结果与终期评估标准进行比较。采用SPSS 18.0软件进行描述性统计分析。结果2010—2020年北京市房山区共报告梅毒病例3260例,年均报告发病率27.99/10万,年均增长0.08%,男女比例基本持平,以25岁年龄组病例数最多,历年病例均以隐性梅毒为主。保障措施与能力建设方面均达标;防治工作方面:感染梅毒的孕产妇所生婴幼儿接受规范诊疗服务的比例为50.00%,梅毒患者接受规范化治疗的比例86.11%,两指标未达标,其余均达标;防治效果中一期和二期梅毒年报告发病率增长幅度为3.80%,未达标,先天梅毒年报告发病率为9.25/10万活产数达到了《梅控规划》的工作要求。结论2010—2020年北京市房山区梅毒防治工作取得了一定成效,但部分指标仍未达标,应继续加强梅毒防治工作,尤其是需提高规范化诊疗的比例同时控制新发梅毒发病率。 相似文献
3.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
4.
《Molecular therapy》2022,30(8):2856-2867
- Download : Download high-res image (173KB)
- Download : Download full-size image
5.
6.
7.
8.
9.
利用空间频域成像技术搭建的成像系统检测多种皮肤病组织的光学参数和生理参数信息,并对比分析讨论不同类型的皮肤病与光学参数、生理参数之间的关系。实验结果表明,病变皮肤组织与正常皮肤组织之间在光学参数、生理参数上存在较大差异,这将为临床医生对皮肤病诊治提供一种新颖、可靠、科学的评估方法。 相似文献
10.
《Value in health》2020,23(8):1027-1033
ObjectivesIn many countries, future unrelated medical costs occurring during life-years gained are excluded from economic evaluation, and benefits of unrelated medical care are implicitly included, leading to life-extending interventions being disproportionately favored over quality of life-improving interventions. This article provides a standardized framework for the inclusion of future unrelated medical costs and demonstrates how this framework can be applied in England and Wales.MethodsData sources are combined to construct estimates of per-capita National Health Service spending by age, sex, and time to death, and a framework is developed for adjusting these estimates for costs of related diseases. Using survival curves from 3 empirical examples illustrates how our estimates for unrelated National Health Service spending can be used to include unrelated medical costs in cost-effectiveness analysis and the impact depending on age, life-years gained, and baseline costs of the target group.ResultsOur results show that including future unrelated medical costs is feasible and standardizable. Empirical examples show that this inclusion leads to an increase in the ICER of between 7% and 13%.ConclusionsThis article contributes to the methodology debate over unrelated costs and how to systematically include them in economic evaluation. Results show that it is both important and possible to include future unrelated medical costs. 相似文献